


### Amendments to the Claims


This listing of claims will replace all prior versions and listings of the claims in the application.

### Listing of claims




1. (Currently Amended) A compound of Formula I:



or a pharmaceutically acceptable salt, N-oxide, hydrate, or solvate thereof,  
wherein



is a pyrrolopyridine moiety of the formula



wherein "Z" is bonded to one of any carbon atom in ring positions 2 to 7, and one of X<sub>5</sub>, X<sub>5a</sub> and X<sub>5b</sub> is an H, hydroxy, or amino substituent on the ring proximal to "Z" attachment at a carbon position that is adjacent to the carbon to which Z is attached and another of X<sub>5</sub>, X<sub>5a</sub>, and X<sub>5b</sub> is a substituent on the ring distal to the carbon to which "Z" is attached at a position alpha to the nitrogen on the distal ring and is selected from the group consisting of H, hydroxy, H<sub>2</sub>N-, (lower alkyl and substituted lower alkyl)HN-, wherein the lower alkyl is optionally substituted with an alkyl group substituent, (hydroxy)HN-, (alkoxy)HN- and (amino)HN-, the remaining one of X<sub>5</sub>, X<sub>5a</sub> and X<sub>5b</sub> is a substituent, as defined below, bonded to any one of the remaining carbon atoms appearing at positions 2 to 7 of the pyrrolopyridine moiety and R<sub>11</sub> is H, alkyl, aralkyl, heteroaralkyl or R<sub>8</sub>(O)CCH<sub>2</sub>-;

Z is alkylene,  $-(CH_2)_rC(O)NR''(CH_2)_s-$ ,  $-(CH_2)_sR''NC(O)(CH_2)_r-$  or  $-(CH_2)_sNR''(CH_2)_r-$

wherein R' and R'' are independently: (a) hydrogen; (b) alkyl optionally substituted with one or more alkyl group substituents; (c) aryl, optionally substituted with one or more ring system substituents; (d) heteroaryl, optionally substituted with one or more ring system substituents; (e) aralkenyl, optionally substituted in the aryl portion with one or more ring system substituents and optionally substituted in the alkenyl portion with one or more substituents selected from halogen and cycloalkyl; (f) heteroaralkenyl, optionally substituted in the heteroaryl portion with one or more ring system substituents and optionally substituted in the alkenyl portion with one or more substituents selected from halogen and cycloalkyl; (g) aralkyl, optionally substituted in the aryl portion with one or more ring system substituents and optionally substituted in the alkyl portion with one or more alkyl group substituents; and (h) heteroaralkyl, optionally substituted in the heteroaryl portion with one or more ring system substituents and optionally substituted in the alkyl portion with one or more alkyl group substituents, wherein "r" is selected independently for each occurrence from 1 and 2 and "s" is selected independently for each occurrence from 0, 1, and 2;

R<sub>1</sub> is selected from: (a) hydrogen; (b) alkyl, optionally substituted with one or more alkyl group substituents; (c) ~~substituted alkyl~~, alkenyl, optionally substituted with one or more substituents selected from halogen and cycloalkyl; (d) ~~substituted alkenyl~~, aralkyl, optionally substituted in the aryl portion with one or more ring system substituents and optionally substituted in the alkyl portion with one or more alkyl group substituents; (e) ~~substituted aralkyl~~, heteroaralkyl, optionally

substituted in the heteroaryl portion with one or more ring system substituents and optionally substituted in the alkyl portion with one or more alkyl group substituents; and (f) a member of the group consisting of substituted heteroaralkyl,  $R'O(CH_2)_x$ ,  $R'O_2C(CH_2)_x$ ,  $R'C(O)(CH_2)_x$ ,  $Y^1Y^2NC(O)(CH_2)_x$ , and  $Y^1Y^2N(CH_2)_x$ ,

wherein  $Y^1$  and  $Y^2$  are independently: (a) hydrogen; (b) alkyl, optionally substituted with one or more alkyl group substituents; (c) aryl, optionally substituted with one or more ring system substituents; (d) heteroaryl, optionally substituted with one or more ring system substituents; (e) aralkyl, optionally substituted in the aryl portion with one or more ring system substituents and optionally substituted in the alkyl portion with one or more alkyl group substituents; and (f) heteroaralkyl, optionally substituted in the heteroaryl portion with one or more ring system substituents and optionally substituted in the alkyl portion with one or more alkyl group substituents, optionally,  $Y^1$  and  $Y^2$  taken together with the N through which  $Y^1$  and  $Y^2$  are linked form a 4 to 7 membered heterocyclyl,

$R'$  is as defined above, and

"x" = 1, 2, 3, 4, or 5;

~~$R'$  and  $R''$  are independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkenyl, substituted aralkenyl, heteroaralkenyl, substituted heteroaralkenyl, aralkyl, substituted aralkyl, heteroaralkyl or substituted heteroaralkyl;~~

$R_2$  is selected from: (a) hydrogen; (b) aralkyl, optionally substituted in the aryl portion with one or more ring system substituents and optionally substituted in the alkyl portion with one or more alkyl group substituents; (c) substituted aralkyl, heteroaralkyl, optionally substituted

in the heteroaryl portion with one or more ring system substituents and optionally substituted in the alkyl portion with one or more alkyl group substituents; (d) ~~substituted heteroaralkyl~~, aralkenyl, optionally substituted in the aryl portion with one or more ring system substituents and optionally substituted in the alkenyl portion with one or more substituents selected from halogen and cycloalkyl; (e) substituted aralkenyl, heteroaralkenyl, optionally substituted in the heteroaryl portion with one or more ring system substituents and optionally substituted in the alkenyl portion with one or more substituents selected from halogen and cycloalkyl; and (f) a member of the group consisting of substituted heteroaralkenyl,  $R_3R_4NC(O)(CH_2)_x-$ ,  $R_3S(O)_p-$ , or and  $R_3R_4NS(O)_p-$

wherein:

"x" is selected from 1, 2, 3, 4, and 5 and "p" is selected independently for each occurrence from 1 and 2;

$R_3$  is selected from the group consisting of: (a) hydrogen; (b) alkyl, optionally substituted with one or more alkyl group substituents; (c) ~~substituted alkyl~~, cycloalkyl, optionally substituted with one or more substituents selected from halogen, methylene, alkyl, fused aryl and fused heteroaryl; (d) ~~cycloalkyl, heterocyclyl, substituted heterocyclyl~~, optionally substituted with one or more substituents selected from alkyl, halogen, aryl, heteroaryl, fused aryl and fused heteroaryl; (e) aryl, substituted aryl, optionally substituted with a ring system substituent; (f) heteroaryl, optionally substituted with a ring system substituent; (g) ~~heteroaryl, aralkyl, substituted aralkyl~~, optionally substituted in the aryl portion with one or more ring system substituents and optionally substituted in the alkyl portion with one or more alkyl group substituents; (h) ~~heteroaralkyl, substituted heteroaralkyl~~, optionally substituted in the heteroaryl portion

with one or more ring system substituents and optionally substituted in the alkyl portion with one or more alkyl group substituents; (i) aralkenyl, substituted aralkenyl, optionally substituted in the aryl portion with one or more ring system substituents and optionally substituted in the alkenyl portion with one or more substituents selected from halogen and cycloalkyl; and (j) heteroaralkenyl or substituted heteroaralkenyl, optionally substituted in the heteroaryl portion with one or more ring system substituents and optionally substituted in the alkenyl portion with one or more substituents selected from halogen and cycloalkyl, optionally  
or R<sub>1</sub> and R<sub>3</sub> taken together with the -N-S(O)<sub>p</sub>- moiety or the -N-S(O)<sub>p</sub>-NR<sub>4</sub>- moiety through which R<sub>1</sub> and R<sub>3</sub> are linked form a 5 to 7 membered heterocycl~~yl~~ or substituted heterocycl~~yl~~ optionally substituted with one or more members selected from the group consisting of alkyl, halogen, aryl, heteroaryl, fused aryl, and fused heteroaryl substituents; and

R<sub>4</sub> is selected from the group consisting of: (a) hydrogen; (b) alkyl, optionally substituted with one or more alkyl group substituents (c) substituted alkyl, cycloalkyl, optionally substituted with one or more substituents selected from halogen, methylene, alkyl, fused aryl and fused heteroaryl; (d) cycloalkyl, aryl, optionally substituted with a ring system substituent; (e) aryl, heteroaryl, substituted heteroaryl, optionally substituted with a ring system substituent; (f) aralkyl, substituted aralkyl, optionally substituted in the aryl portion with one or more ring system substituents and optionally substituted in the alkyl portion with one or more alkyl group substituents; (g) heteroaralkyl or substituted heteroaralkyl, optionally substituted in the heteroaryl portion

with one or more ring system substituents and optionally substituted in the alkyl portion with one or more alkyl group substituents, optionally  $\text{or-R}_3$  and  $\text{R}_4$  taken together with the nitrogen to which  $\text{R}_3$  and  $\text{R}_4$  are attached form a 4 to 7 membered heterocyclyl, optionally substituted with one or more substituents selected from alkyl, halogen, aryl, heteroaryl, fused aryl, and fused heteroaryl or substituted heterocyclyl;

$\text{X}_1$  and  $\text{X}_{1a}$  are independently selected from: (a) H; (b) alkyl, optionally substituted with one or more alkyl group substituents; (c) substituted alkyl, aryl, optionally substituted with one or more ring system substituents; (d) substituted aryl, aralkyl, optionally substituted in the aryl portion with one or more ring system substituents and optionally substituted in the alkyl portion with one or more alkyl group substituents; (e) substituted aralkyl, heteroaryl, optionally substituted with one or more ring system substituents; (f) substituted heteroaryl, heteroaralkyl, optionally substituted in the heteroaryl portion with one or more ring system substituents and optionally substituted in the alkyl portion with one or more alkyl group substituents, optionally, substituted heteroaralkyl, or  $\text{X}_1$  and  $\text{X}_{1a}$  taken together form oxo;

~~$\text{X}_2$  and  $\text{X}_{2a}$  taken together form oxo;~~

$\text{X}_3$  is selected from: (a) H; (b) hydroxyl; (c) alkyl, optionally substituted with one or more alkyl group substituents; (d) substituted alkyl, aryl, optionally substituted with one or more ring system substituents; (e) substituted aryl, heteroaryl, optionally substituted with one or more ring system substituents; (f) heteroaryl, aralkyl, optionally substituted in the aryl portion with one or more ring system substituents and optionally substituted in the alkyl portion with one or more alkyl group

substituents; (g) substituted aralkyl, heteroaralkyl, substituted heteroaralkyl, optionally substituted in the heteroaryl portion with one or more ring system substituents and optionally substituted in the alkyl portion with one or more alkyl group substituents, optionally, or X<sub>3</sub> and one of X<sub>1</sub> and X<sub>1a</sub> taken together form a 4 to 7 membered cycloalkyl;

X<sub>4</sub> is selected from (a) H; (b) alkyl, substituted alkyl, optionally substituted with one or more alkyl group substituents; and (c) aralkyl or substituted aralkyl, optionally substituted in the aryl portion with one or more ring system substituents and optionally substituted in the alkyl portion with one or more alkyl group substituents;

one of X<sub>5</sub>, X<sub>5a</sub>, and X<sub>5b</sub> which has not been otherwise selected is selected from H, R<sub>5</sub>R<sub>6</sub>N-, (hydroxy)HN-, (alkoxy)HN-, or (amino)HN-, R<sub>7</sub>O-, R<sub>5</sub>R<sub>6</sub>NCO-, R<sub>5</sub>R<sub>6</sub>NSO<sub>2</sub>-, R<sub>7</sub>CO-, halo, cyano, nitro and R<sub>8</sub>(O)CCH<sub>2</sub>-;

~~Y<sup>1</sup> and Y<sup>2</sup> are independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl or substituted heteroaralkyl, or Y<sup>1</sup> and Y<sup>2</sup> taken together with the N through which Y<sup>1</sup> and Y<sup>2</sup> are linked form a 4 to 7 membered heterocyclyl;~~

R<sub>5</sub> and R<sub>6</sub> are independently selected from (a) H; (b) lower alkyl, optionally substituted with one or more alkyl group substituents; and (c) a substituent comprising selecting or substituted lower alkyl, or one of R<sub>5</sub> and R<sub>6</sub> is to be H and the other of R<sub>5</sub> and R<sub>6</sub> is to be R<sub>8</sub>(O)CCH<sub>2</sub>- or lower acyl;

R<sub>7</sub> is selected from H, lower alkyl which is optionally substituted with one or more alkyl group substituents or substituted lower alkyl, lower acyl or and R<sub>8</sub>(O)CCH<sub>2</sub>- ;



~~R<sub>8</sub> is selected from H, optionally substituted lower alkyl which is substituted with one or more alkyl group substituents, alkoxy or and hydroxy;~~

~~m is 1;~~

~~p and r are independently 1 or 2;~~

~~s is 0, 1 or 2; and~~

~~x is 1, 2, 3, 4, or 5.~~

2. (Currently Amended) The compound of claim 1, wherein:

Z is alkylene;

R<sub>1</sub> is selected from: (a) hydrogen; (b) alkyl, optionally substituted with one or more alkyl group substituents; (c) substituted alkyl, aralkyl, optionally substituted in the aryl portion with one or more ring system substituents and optionally substituted in the alkyl portion with one or more alkyl group substituents; (d) substituted aralkyl, heteroaralkyl, substituted heteroaralkyl, optionally substituted in the heteroaryl portion with one or more ring system substituents and optionally substituted in the alkyl portion with one or more alkyl group substituents; (e) a member of the group consisting of R'O(CH<sub>2</sub>)<sub>x</sub>-, R'O<sub>2</sub>C(CH<sub>2</sub>)<sub>x</sub>-, Y<sup>1</sup>Y<sup>2</sup>NC(O)(CH<sub>2</sub>)<sub>x</sub>-, and or Y<sup>1</sup>Y<sup>2</sup>N(CH<sub>2</sub>)<sub>x</sub>-;

R' is selected from: (a) hydrogen; (b) alkyl, optionally substituted with one or more alkyl group substituents; (c) substituted alkyl, aralkyl, optionally

substituted in the aryl portion with one or more ring system substituents and optionally substituted in the alkyl portion with one or more alkyl group substituents; and (d) substituted aralkyl, heteroaralkyl, substituted heteroaralkyl, optionally substituted in the heteroaryl portion with one or more ring system substituents and optionally substituted in the alkyl portion with one or more alkyl group substituents;

$R_2$  is  $R_3S(O)_p-$  or  $R_3R_4NS(O)_p-$ ;


$R_3$  is selected from: (a) alkyl, optionally substituted with one or more alkyl group substituents; (b) substituted alkyl, cycloalkyl, optionally substituted with one or more substituents selected from halogen, methylene, alkyl, fused aryl, and fused heteraryl; (c) cycloalkyl, heterocyclyl, substituted heterocyclyl, optionally substituted with one or more substituents selected from alkyl, halogen, aryl, heteroaryl, fused aryl and fused heteroaryl; (d) aryl, substituted aryl, optionally substituted with one or more ring system substituents; (e) heteroaryl, substituted heteroaryl, optionally substituted with one or more ring system substituents; (f) aralkyl, substituted aralkyl, optionally substituted in the aryl portion with one or more ring system substituents and optionally substituted in the alkyl portion with one or more alkyl group substituents; (f) substituted aralkyl, heteroaralkyl, substituted heteroaralkyl, optionally substituted in the heteroaryl portion with one or more ring system substituents and optionally substituted in the alkyl portion with one or more alkyl group substituents; (g) aralkenyl, substituted aralkenyl, optionally substituted in the aryl portion with one or more ring system substituents and optionally substituted in the alkenyl portion with one or more substituents selected from halogen and cycloalkyl; (h) hetero-aralkenyl or substituted heteroaralkenyl, optionally substituted in the heteroaryl portion with one or more ring system substituents and optionally substituted in the alkenyl portion with one or

more substituents selected from halogen and cycloalkyl, or optionally, R<sub>1</sub> and R<sub>3</sub> together with the -N-S(O)<sub>p</sub>- moiety or the -N-S(O)<sub>p</sub>-NR<sub>4</sub>- moiety through which R<sub>1</sub> and R<sub>3</sub> are linked form a 5 to 7 membered heterocyclyl, moiety optionally substituted with one or more substituents selected from alkyl, halogen, aryl, heteroaryl, fused aryl and fused heteroaryl or substituted heterocyclyl;

R<sub>4</sub> is selected from: (a) alkyl, optionally substituted with one or more alkyl group substituents; (b) substituted alkyl, cycloalkyl, optionally substituted with one or more substituents selected from halogen, methylene, alkyl, fused aryl and fused heteroaryl; (c) cycloalkyl, aryl, substituted aryl, optionally substituted with one or more ring system substituents; (d) heteroaryl, substituted heteroaryl, optionally substituted with one or more ring system substituents; (e) aralkyl, substituted aralkyl, optionally substituted in the aryl portion with one or more ring system substituents and optionally substituted in the alkyl portion with one or more alkyl group substituents; (f) substituted aralkyl, heteroaralkyl, substituted heteroaralkyl, optionally substituted in the heteroaryl portion with one or more ring system substituents and optionally substituted in the alkyl portion with one or more alkyl group substituents, or optionally, R<sub>3</sub> and R<sub>4</sub> taken together with the nitrogen to which R<sub>3</sub> and R<sub>4</sub> are attached form a 4 to 7 membered heterocyclyl, optionally substituted with one or more substituents selected from alkyl, halogen, aryl, heteroaryl, fused aryl and fused heteroaryl or substituted heterocyclyl; and Y<sup>1</sup> and Y<sup>2</sup> are independently selected from: (a) hydrogen; (b) alkyl, optionally substituted with one or more alkyl group substituents; (c) aryl, optionally substituted with a ring system substituent; (d) aralkyl, substituted aralkyl, optionally substituted in the aryl portion with one or more ring system substituents and optionally substituted in the alkyl portion with one or more alkyl group substituents; and (e) heteroaralkyl or optionally substituted heteroaralkyl, optionally substituted in the heteroaryl

portion with one or more ring system substituents and optionally  
substituted in the alkyl portion with one or more alkyl group substituents, or  
optionally, Y<sup>1</sup> and Y<sup>2</sup> taken together with the N through which Y<sup>1</sup> and Y<sup>2</sup>  
are linked form a 4 to 7 membered heterocyclyl; or  
a pharmaceutically acceptable salt, N-oxide, hydrate or solvate thereof.

3. (Cancelled)
4. (Cancelled)
5. (Cancelled)
6. (Original) The compound of claim 1 wherein R<sub>2</sub> is selected from the group consisting of




7. (Cancelled)
8. (Currently Amended) The compound of claim 1 wherein R<sub>1</sub> is selected from the group consisting of H, heteroaralkyl, substituted heteroaralkyl, which is

optionally substituted in the heteroaryl portion with one or more ring system substituents and optionally substituted in the alkyl portion with one or more alkyl group substituents, ~~aralkyl, substituted aralkyl,~~ which is optionally substituted in the aryl portion with one or more ring system substituents and optionally substituted in the alkyl portion with one or more alkyl group substituents, and ~~alkyl or substituted alkyl,~~ which is optionally substituted with one or more alkyl group substituents.

9. (Original) The compound of claim 1 wherein  $R_2$  is  $R_3S(O)_p$ .
10. (Original) The compound of claim 9 wherein p is 2.
11. (Currently Amended) The compound of claim 9 wherein  $R_3$  is selected from the group consisting of phenyl, ~~substituted phenyl, naphthyl, substituted naphthyl, thienyl, substituted thienyl, benzothienyl, substituted benzothienyl, thienopyridyl, substituted thienopyridyl, quinoliny, and substituted quinoliny,~~ isoquinoliny or optionally substituted isoquinoliny, each of which may optionally be substituted by one or more ring system substituents.
12. (Previously Presented) The compound of claim 1 wherein Z is methylenyl.
13. (Cancelled)
14. (Original) The compound of claim 1 wherein each of  $X_1$ ,  $X_{1a}$ ,  $X_3$  and  $X_4$  is H.
15. (Cancelled)
16. (Cancelled)
17. (Cancelled)
18. (Cancelled)

19. (Cancelled)
20. (Cancelled)
21. (Cancelled)
22. (Previously Presented) The compound of claim 1, wherein Z is bonded to the 5 membered ring of said pyrrolopyridine moiety.
23. (Cancelled).
24. (Previously Presented) The compound of claim 1 wherein one of X<sub>5</sub>, X<sub>5a</sub> and X<sub>5b</sub> is hydroxy or amino.
25. (Currently Amended) The compound of claim 1 wherein said one of X<sub>5</sub>, X<sub>5a</sub> and





X<sub>5b</sub> that is a substituent on the ring distal to Z and alpha to nitrogen thereof is H or (H, lower alkyl which is optionally substituted with one or more alkyl group substituents, ~~substituted lower alkyl~~, (hydroxy or amino)HN-.

26. (Previously Presented) A compound according to claim 1 which is selected from 1-(4-Aminoquinazolin-7-ylmethyl)-3-(S)-[(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)amino] pyrrolidin-2-one; 2-(5-Chlorothiophen-2-yl)ethenesulfonic acid [2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-yl-methyl)pyrrolidin-3-(R)-yl]amide; {[2-(5-Chlorothiophen-2-yl)ethenesulfonyl]-[2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-yl-methyl)pyrrolidin-3-(R)-yl]amino}acetic acid isopropyl ester; 5'Chloro-[2,2']bithiophenyl-5-sulfonic acid [2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-yl-methyl)-pyrrolidin-3(S)-yl]-amide; and 2-(5-Chloro-thiophen-2-yl)-ethenesulfonic acid [2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-yl-methyl)-pyrrolidin-3-(S)-yl]-amide.
27. (Previously Presented) A compound according to claim 1 which is selected from 2-(5-Chloro-thiophen-2-yl)-ethenesulfonic acid [2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-yl-methyl)-pyrrolidin-3-(S)-yl]-amide and thieno[3,2-b]pyridine-2-


sulfonic acid [2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-pyrrolidin-3-(S)-yl]-  
amide ditrifluoroacetate.


28. (Previously Presented) A compound according to claim 1 wherein  $X_1$ ,  $X_{1a}$ ,  $X_3$  and  $X_4$  are H; and  $R_2$  is a radical selected from the group consisting of






















29. (Currently Amended) A compound of the Formula †




wherein ~~R<sub>4</sub>, X<sub>4</sub>, X<sub>1a</sub>, X<sub>3</sub> and X<sub>4</sub> are H, X<sub>2</sub> and X<sub>2a</sub> taken together are an exo~~  
~~group;~~

















is selected from the group consisting of



and



R<sub>2</sub> is a radical selected from the group consisting of



30. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable amount of a compound according to claim I and a pharmaceutically acceptable carrier.
31. (Original) A method for treating a patient suffering from a physiological disorder capable of being modulated by inhibiting an activity of Factor Xa comprising administering to the patient a therapeutically effective amount of a compound according to claim 1.
32. (Original) The method according to claim 31 wherein the physiological disorder is abnormal thrombus formation, acute myocardial infarction, unstable angina, thromboembolism, acute vessel closure associated with thrombolytic therapy or percutaneous transluminal coronary angioplasty, transient ischemic attacks, stroke, pathologic thrombus formation occurring in the veins of the lower extremities following abdominal, knee and hip surgery, a risk of pulmonary thromboembolism, or disseminated systemic intravascular coagulopathy occurring in vascular systems during septic shock, certain viral infections or cancer.
33. (Original) The method according to claim 31 wherein the physiological disorder is abnormal thrombus formation, acute myocardial infarction, unstable angina, thromboembolism, acute vessel closure associated with thrombolytic therapy, transient ischemic attacks, restenosis post coronary or venous angioplasty, pathologic thrombus formation occurring in the veins of the lower extremities following abdominal, knee and hip surgery or a risk of pulmonary thromboembolism.
34. (Original) The method according to claim 31 wherein the physiological disorder is stroke, vessel luminal narrowing, or disseminated systemic intravascular coagulopathy occurring in vascular systems during septic shock, certain viral infections or cancer.

35. (Original) The method of claim 31 wherein said compound according to claim 1 is administered in combination with at least one other agent selected from diagnostic agents, cardioprotective agents, direct thrombin inhibiting agents, anticoagulant agents, antiplatelet agents and fibrinolytic agents.
36. (Original) The method of claim 35 wherein said other agent is selected from standard heparin, low molecular weight heparin, direct thrombin inhibitors, aspirin, fibrinogen receptor antagonists, streptokinase, urokinase and tissue plasminogen activator.
37. (Original) The method of claim 36 wherein said other agent is selected from direct thrombin inhibitors and fibrinogen receptor antagonists.
38. (Original) The method of claim 37 wherein said thrombin inhibitor is selected from boroarginine derivatives, boroptides, hirudin, argatroban and the pharmaceutically acceptable salts, prodrugs, derivatives and analogs thereof.
39. (Original) The pharmaceutical composition of claim 30 further comprising at least one other agent selected from diagnostic agents, cardioprotective agents, direct thrombin inhibiting agents, anticoagulant agents, antiplatelet agents and fibrinolytic agents.
40. (Original) The pharmaceutical composition of claim 39 wherein said other agent is selected from standard heparin, low molecular weight heparin, direct thrombin inhibitors, aspirin, fibrinogen receptor antagonists, streptokinase, urokinase and tissue plasminogen activator.
41. (Original) The pharmaceutical composition of claim 40 wherein said other agent is selected from direct thrombin inhibitors and fibrinogen receptor antagonists.
42. (Cancelled)